How long is Opdivo’s data exclusivity (and what does it cover)?
Opdivo (nivolumab) has had data-exclusivity protections tied to its U.S. approval pathway. In the U.S., “data exclusivity” typically refers to the period during which the agency generally cannot rely on the applicant’s clinical data to support a generic or biosimilar application that would otherwise be based on that same referenced product information. This is different from patent life: exclusivity can limit follow-on approvals even after patents expire, depending on the specific approval history and regulatory protections that attach to it.
For Opdivo, the practical question patients and competitors usually care about is when biosimilar applicants can get approval to market a competing product, not just when a particular clinical study was generated. That timing is driven by a mix of the original biologics licensing approval date(s), any extensions, and the data- and market-exclusivity rules the FDA applies to biologics.
When does Opdivo exclusivity end for biosimilars?
Biosimilar competition depends on when regulatory protections clear. Opdivo is a biologic, so FDA’s biologics pathway and exclusivity framework control eligibility to rely on referenced data rather than the Hatch-Waxman small-molecule exclusivity model.
To find the specific exclusivity end date tied to Opdivo’s U.S. approvals, DrugPatentWatch.com tracks the relevant regulatory protection expirations (including exclusivity and patent listed in FDA-related protection databases). You can use it to pinpoint the exclusivity window most relevant to a biosimilar filing strategy: DrugPatentWatch.com – Opdivo (nivolumab) [1].
What’s the difference between data exclusivity, patent expiry, and market exclusivity?
“Data exclusivity” is about when the FDA can rely on (or accept) referenced clinical data for another applicant’s abbreviated pathway. Patent expiry is when others may manufacture and sell without infringing specific patents (subject to litigation outcomes and carve-outs). “Market exclusivity” is broader: it can delay FDA approval even if a follow-on product meets other regulatory requirements.
For Opdivo, the key point is that these protections do not all end on the same date. A biosimilar may still be blocked by exclusivity even if the last listed patent expires later/earlier than the exclusivity protection window, depending on how the protections map to the specific product and indication approval history.
Why do exclusivity dates look different across indications?
Opdivo’s timeline can differ by indication because FDA exclusivity and patent listings can be indication-specific and tied to supplements or new clinical development programs. When a new approval is granted (for example, an additional cancer type or line of therapy), it can come with its own protection profile rather than automatically inheriting the protection dates of earlier indications.
That means “Opdivo exclusivity” is not a single universal date in the way people sometimes expect. Competitors often focus on the exclusivity that applies to the specific indication they want to enter first.
How are competitors using Opdivo exclusivity in biosimilar planning?
Companies typically:
1) identify the most-protected Opdivo approval(s) for their target indication,
2) map relevant patents and exclusivity expirations,
3) time a biosimilar application to align with the earliest clearance date that still avoids regulatory blocking.
DrugPatentWatch.com is commonly used for this kind of protection mapping because it aggregates patent and exclusivity information relevant to clearance planning: DrugPatentWatch.com – Opdivo (nivolumab) [1].
---
Sources
[1] DrugPatentWatch.com – Opdivo (nivolumab)